InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...

Activation of the ‘complement system’ helps trigger dangerous sickle-cell-disease outcome Research in mice suggests this system plays a key role in acute chest syndrome and offers a potential ...

The hazard of the progression of intermediate age-related macular degeneration (iAMD) was higher in those whose complement pathways were not regulated.

Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases.

A 32-year-old woman was admitted with flank pain, fever, and hypoxemia. Imaging showed multifocal pulmonary opacities, pulmonary embolism, and renal vein thromboses. A diagnosis was made.

Researchers had thought complement could be used to fight cancers as part of an antibody-based vaccine, as antibody binding is one of the factors that can set off a complement cascade. However, some ...

Complement activation via the alternative pathway with subsequent generation of the C5a complement fragment has an important role in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated ...

About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and ...

InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize ...

Study reveals ketamine's potent anti-inflammatory effects on neurological disorders, showing promise for treating major depressive disorder through modulation of neuroimmune pathways.